The scoring system employs both clinical and genomic data to predict treatment response (pCR) and survival in early-stage HER2-positive breast cancer based on a 27-gene expression plus clinical features, tumor size, and nodal staging. This evidence concerns the gene ERBB2 and neoplasm.